Croda International (LON:CRDA – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at Berenberg Bank in a report issued on Thursday, MarketBeat.com reports. They currently have a GBX 3,800 ($50.60) price target on the stock. Berenberg Bank’s target price would indicate a potential upside of 27.91% from the stock’s current price.
Croda International Price Performance
Croda International stock opened at GBX 2,970.73 ($39.56) on Thursday. The company has a current ratio of 2.72, a quick ratio of 2.25 and a debt-to-equity ratio of 30.90. The company has a market capitalization of £4.15 billion, a price-to-earnings ratio of 25.53, a PEG ratio of 1.40 and a beta of 0.74. The stock’s 50 day moving average is GBX 2,960.54 and its 200-day moving average is GBX 3,294.46. Croda International has a 12 month low of GBX 2,551 ($33.97) and a 12 month high of GBX 4,932 ($65.67).
Croda International (LON:CRDA – Get Free Report) last released its quarterly earnings results on Tuesday, February 25th. The company reported GBX 142.60 ($1.90) EPS for the quarter. Croda International had a net margin of 9.98% and a return on equity of 6.96%. Equities research analysts expect that Croda International will post 181.8307268 EPS for the current year.
Insider Buying and Selling at Croda International
About Croda International
Founded in 1925 with the aim of turning bio-based raw materials into innovative ingredients, Croda International is a speciality chemicals company focused on consumer care and life sciences markets. The company is focused on creating, making and selling innovative ingredients that deliver real benefits to a diverse range of customers and employs more than 6,000 people around the world.
Featured Stories
- Five stocks we like better than Croda International
- Asset Allocation Strategies in Volatile Markets
- Short Sellers Gave Up on These 3 Names Recently
- How to Invest in Small Cap Stocks
- 3 Boring Stocks Outperforming the Market This Year
- Low PE Growth Stocks: Unlocking Investment Opportunities
- If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy
Receive News & Ratings for Croda International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Croda International and related companies with MarketBeat.com's FREE daily email newsletter.